Ligand validation:6JYF

OLA: OLEIC ACID

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6JYF_OLA_A_305	36%	56%	0.197	0.888	0.8	0.88	1	1	1	0	100%	1
6JYF_OLA_A_304	33%	47%	0.154	0.885	0.94	1.11	1	2	2	0	70%	0.7
6JYF_OLA_A_306	32%	53%	0.154	0.846	0.82	1.01	1	2	0	0	90%	0.9
6JYF_OLA_A_308	32%	43%	0.109	0.853	1.03	1.18	1	1	0	0	60%	0.6
6JYF_OLA_A_311	23%	70%	0.172	0.896	0.34	0.81	-	-	0	0	45%	0.45
6JYF_OLA_A_313	22%	50%	0.146	0.856	0.71	1.22	-	-	0	0	45%	0.45
6JYF_OLA_A_307	21%	52%	0.166	0.867	0.66	1.18	-	1	1	0	50%	0.5
6JYF_OLA_A_309	20%	58%	0.166	0.857	0.97	0.65	1	-	0	0	50%	0.5
6JYF_OLA_A_310	18%	76%	0.202	0.915	0.33	0.61	-	-	0	0	30%	0.3
6JYF_OLA_A_314	11%	60%	0.204	0.799	0.8	0.72	1	-	0	0	55%	0.55
6JYF_OLA_A_312	5%	48%	0.35	0.854	0.7	1.28	-	1	0	0	45%	0.45
5G28_OLA_A_1271	60%	64%	0.097	0.898	0.77	0.61	1	-	0	0	90%	0.9
7CRL_OLA_A_305	49%	39%	0.134	0.878	1	1.39	1	2	1	0	100%	0.7582
7CRJ_OLA_A_305	48%	49%	0.13	0.87	0.9	1.05	1	2	0	0	100%	0.8453
6JYC_OLA_A_304	47%	47%	0.132	0.923	0.95	1.1	1	1	2	0	70%	0.7
6JY7_OLA_A_304	46%	46%	0.121	0.91	0.95	1.15	1	2	1	0	70%	0.7
6DJ6_OLA_B_402	92%	68%	0.081	0.971	0.55	0.69	-	-	0	0	100%	1
1LFO_OLA_A_128	79%	59%	0.097	0.943	0.78	0.79	1	-	0	0	100%	1
6E12_OLA_B_301	65%	45%	0.13	0.932	1.01	1.12	1	2	2	0	100%	1
8GEW_OLA_A_202	64%	57%	0.138	0.938	0.69	0.94	-	2	0	0	100%	0.44
5IU4_OLA_A_2406	64%	62%	0.105	0.903	0.69	0.75	-	1	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.